INCB160058 + famotidine

INCB160058 + famotidine is a hypothetical combination of two distinct pharmaceutical agents: INCB160058, an investigational oral small molecule inhibitor of the JAK2V617F pseudokinase (JH2) domain developed for selective targeting of JAK2V617F-mutant myeloproliferative neoplasms, and famotidine, an oral H2-histamine receptor antagonist widely used to reduce gastric acid secretion. INCB160058 acts by binding with high specificity to the JAK2 JH2 domain, blocking cytokine-independent mutant JAK2 signaling while sparing normal cytokine-dependent activity, leading to elimination of JAK2V617F-positive malignant clones[4]. Famotidine acts as a competitive antagonist at the H2-receptor on gastric parietal cells, resulting in reduced acid secretion. There is no evidence or approved therapeutic product for a fixed-dose combination of these two agents, but both might be co-administered for investigator-initiated or off-label research—especially to address potential upper gastrointestinal adverse events related to JAK inhibitor therapy or in clinical trials where famotidine is used as supportive care.